
MEDIA RELEASE

World's first zero carbon emission autoinjector from Ypsomed

Burgdorf, 02 October 2020, 7.00 a.m. – Ypsomed has developed the world's first zero carbon emission prefilled autoinjector. The YpsoMate Zero is based on the proven YpsoMate autoinjector platform that offers convenient handling and patient safety. The new YpsoMate Zero uses alternative biopolymers and a novel packaging design that follows the principles of circular product design.

Self-medication of drugs makes everyday life easier for people with chronic diseases. Easy-to-use self-injection systems such as the YpsoMate autoinjector for pre-filled syringes contribute to shifting the point of care from a healthcare setting to the home. At-home treatment of chronic diseases improves access to healthcare and lowers overall costs. It also helps to minimise the environmental impact by reducing the need for travel or the use of hospital infrastructure and resources.

However, its single-use nature has put the pre-filled autoinjector at the forefront of the global plastic challenge, urging Ypsomed to take action. "We must take responsibility for the environmental effects of our products. This is why we develop injection devices that minimise the impact of self-medication on the environment," elaborates Ypsomed's CEO Simon Michel on the vision of injection devices with zero carbon footprint. Ypsomed subjected the YpsoMate to a comprehensive life cycle assessment to highlight its environmental hot spots and enable data-driven design optimisations. As a result, Ypsomed developed the YpsoMate Zero. This environment-friendly device uses alternative materials and implements improvements along the supply chain without compromising on usability and patient safety. Further, Ypsomed will compensate the remaining carbon footprint through CO₂ certificates from third parties and own activities, such as its reforestation program in Eastern Africa.

Zero carbon emissions by 2030

Sustainability is one of Ypsomed's strategic pillars. The company is determined to achieve net zero carbon emissions by 2030. Therefore, Ypsomed seeks to drive circular product design that minimises the environmental impact of self-medication along the entire value chain. The YpsoMate Zero is the first step towards the goal of self-care solutions with zero impact on the environment. The product demonstrates that the company assumes its social and societal responsibility and it proves the ambition to pioneering the development of new technologies.

Contact

Thomas Kutt, Head of Investor Relations
+41 34 424 35 55 / thomas.kutt@ypsomed.com

About Ypsomed Holding AG

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees.